PDE5A and interstitial lung disease: Several trials have investigated whether drugs effective for primary PH (group 1) are also effective for PH-ILD (group 3), including Phosphodiesterase-5 (PDE5) inhibitors, Endothelin receptor antagonists (ERAs), soluble guanylate cyclase (sGC), and inhaled vasodilators.